-
公开(公告)号:GB201321733D0
公开(公告)日:2014-01-22
申请号:GB201321733
申请日:2013-12-09
Applicant: UCB PHARMA SA
Abstract: A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号:GB201321732D0
公开(公告)日:2014-01-22
申请号:GB201321732
申请日:2013-12-09
Applicant: UCB PHARMA SA
Abstract: A series of substituted imidazo[l,2-b][l,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号:AU2010209790B2
公开(公告)日:2014-01-16
申请号:AU2010209790
申请日:2010-01-27
Applicant: UCB PHARMA SA
Inventor: CUYPERS SERGE , BERWAER MONIQUE , FANARA DOMENICO , BARILLARO VALERY , LARBANOIX MARTINE , DARGELAS FREDERIC
IPC: A61K9/20 , A61K31/4015
Abstract: The present invention relates to an immediate release formulation of pharmaceutical compounds.
-
公开(公告)号:AU2012283388A1
公开(公告)日:2014-01-09
申请号:AU2012283388
申请日:2012-07-13
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector, comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen binding fragment thereof specifically binding to CD154.
-
公开(公告)号:IL192603A
公开(公告)日:2013-12-31
申请号:IL19260308
申请日:2008-07-03
Applicant: UCB PHARMA SA
IPC: A61K20060101 , A61P20060101 , C07D20060101
Abstract: Novel processes for the preparation of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety and intermediates thereto are provided. The compounds prepared by the present processes may be useful, for example, as selective inhibitors of human MEK (MAPKK) enzymes, and are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.
-
公开(公告)号:ES2429445T3
公开(公告)日:2013-11-14
申请号:ES08806216
申请日:2008-09-04
Applicant: UCB PHARMA SA
Inventor: MARSHALL DIANE , SHAW STEVAN
Abstract: Uso de un anticuerpo o fragmento funcionalmente activo, que inhibe de manera selectiva el polipéptido de IL-6 oel polipéptido de IL-6R para la fabricación de un medicamento para el tratamiento y/o la profilaxis de laglomerulonefritis asociada con el síndrome de Goodpasture.
-
公开(公告)号:EA018736B1
公开(公告)日:2013-10-30
申请号:EA201001402
申请日:2009-03-02
Applicant: UCB PHARMA SA
Inventor: SCHENKEL ERIC , POULAIN CLAIRE , DODELET BERTRAND , FANARA DOMENICO
IPC: A61K9/08 , A61K31/4015
Abstract: Визобретенииописанстабильныйфармацевтическийраствор, способегополученияи терапевтическогоприменения.
-
公开(公告)号:CA2869216A1
公开(公告)日:2013-10-24
申请号:CA2869216
申请日:2013-04-19
Applicant: UCB PHARMA SA
Inventor: MICHEL ANNE , DOWNEY PATRICK , MONTEL FLORIAN , SCHELLER DIETER , CHRISTOPHE BERNARD
IPC: A61K31/395 , A61K31/4439 , A61K31/4523 , A61K31/4985 , A61P25/16
Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.
-
公开(公告)号:GB201314381D0
公开(公告)日:2013-09-25
申请号:GB201314381
申请日:2013-08-12
Applicant: UCB PHARMA SA
Abstract: Provided is a manual drive unit for use with a cassette unit comprising a cassette unit housing containing there within a syringe comprising a barrel for containing a volume of a liquid drug formulation; a hollow needle at a front end of the barrel, the hollow needle defining a needle tip for dispensing of the liquid drug formulation; and a plunger that is axially movable within the barrel. The manual drive unit comprises a manual drive unit housing defining a docking cavity and a needle delivery aperture, wherein said docking cavity is arranged for docking receipt of the cassette unit at a docking position; and received by the manual drive unit housing and axially movable relative thereto, a manually operable drive transfer element for transferring axial drive to the plunger of the syringe for moving the plunger into the barrel of the syringe to eject at least part of the volume of liquid drug formulation.
-
公开(公告)号:CA2865261A1
公开(公告)日:2013-08-29
申请号:CA2865261
申请日:2013-02-22
Applicant: UCB PHARMA SA
Inventor: HUMPHREYS DAVID PAUL , PETERS SHIRLEY JANE
IPC: C07K16/00
Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterised in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.
-
-
-
-
-
-
-
-
-